COMTiMS

Treatment tested

• Methylprednisolone

  Glucocorticoid receptor agonist

Other measures (4)

Inclusion Criteria: * Age between 18 and 65 years old * Progressive form of MS (Eg. primary or secondary progressive MS) * Duration of progressive phase at least 1 year * Progression of at least 1 EDSS point for the last 2 years or at least ½ EDSS point in patients with EDSS > 5,5 * Progressin in 2 FS point * EDSS \</= 6,5 * Signed informed consent and written authority Exclusion Criteria: * Pregnancy and breast feeding * Lack of secure contraception for women of child-bearing age (hormonal or intrauterine device) * Attack in the last month previous to inclusion * Treatment with methylprednisolone or cyclic methylprednisolone the 3 previous month before inclusion * Treatment with interferon-beta, Glatiramer acetate, immunglobulin G or other immunomodulating treatment the 3 previous month before inclusion * Treatment with Mitoxantrone, ciclofosfamide, Azathioprin or other immunosuppressive treatment the 6 previous month before inclusion * Previous treatment with drugs which the treating physician finds could have influence on the study results * Diseases associated with immune defects * Treatment with other anticoagulant than acetyl salicyl acid * Malignancy * Diabetes Mellitus * Renal insufficiency or S-Creatinine > 150 mmol/l * Acute or chronic infections with hepatitis B og C virus, HIV or other infections which the treating physician finds relevant * Psychiatric illness or other conditions which can impair the collaboration of the patient participating in the study * Contra-indication to MRI * Hypersensitivity to methylprednisolone * Osteoporosis

The purpose of this study is to determine whether cyclic oral methylprednisolone once every month has an effect on the intrathecal inflammation in patients suffering from progressive multiple sclerosis.